See below.
I agree with Seawolf re state of play.
I also think that significant that we are not seeing directors (particularly Birchmore) bailing out.
Birchmore not going to muck around if project is going nowhere.
That said, agree with general sentiment that needs to be more disclosure. Company not helping itself in that regard.
BUSH
* * * * * *
From http://www.atrico.com.au
Brian Leedman
Corporate Advisor
Brian is a marketing and communications specialist with more than 15 years combined experience at Westpac Banking Corporation, Ernst & Young and pSivida Corp.
As Vice President, Investor Relations of pSivida Corp., a global drug delivery company based in Boston, he led international capital raising missions that netted in excess of US$40m and has presented at prestigious health care conferences. Prior to that, Brian was the Group Marketing Manager of Ernst & Young in Perth, where he was responsible for building industry relationships, public relations, and brand management.
Brian holds a Bachelor of Economics and a Master of Business Administration from the University of Western Australia where he also served for two years as President of the Graduate Management Association. Brian was a 2004 winner of the WA Business News 40under40 Awards and is a Board Member of the Australia Israel Chamber of Commerce and The Perth City Heritage Appeal. He is an active speaker in the conference circuit and has chaired a number of national investor relations and capital raising conferences in Sydney and Perth.
* * * * * * * *
Focus
Atrico’s core market segment are businesses that have:
Differentiated technology or intellectual property,
Revenues <$50m and unsuitable for large investment banks, and
Potential for high growth.
We focus on the following sectors due to our team’s industry background, transaction track record, and relationships:
Information and communications technologies (ICT) and software
Mining and oil & gas
Cleantech
Healthcare and biotech
Transaction advisory services
Capital raising
Trade sale and divestment
Merger and acquisition
Corporate restructuring
Licensing transactions
Strategic alliances (manufacturing, distribution, sales) planning and execution
Add to My Watchlist
What is My Watchlist?